Original language | English (US) |
---|---|
Pages (from-to) | 208-214 |
Number of pages | 7 |
Journal | Movement Disorders Clinical Practice |
Volume | 8 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2021 |
Keywords
- clinical scales
- data collection
- electronic health records
- medical information exchange
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Movement Disorders Clinical Practice, Vol. 8, No. 2, 02.2021, p. 208-214.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Toward e-Scales
T2 - Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales
AU - MDS Rating Scales Program Electronic Development Committee and the MDS Technology Taskforce
AU - Monje, Mariana H.G.
AU - Fuller, Rebecca L.M.
AU - Cubo, Esther
AU - Mestre, Tiago A.
AU - Tan, Ai Huey
AU - Stout, Julie C.
AU - Ali, Shazia
AU - Chahine, Lana
AU - Dujardin, Kathy
AU - Fitzer-Attas, Cheryl J.
AU - Youn, Jinyoung
AU - Bloem, Bastiaan R.
AU - Horak, Fay B.
AU - Merola, Aristide
AU - Reilmann, Ralf
AU - Paul, Serene S.
AU - Dorsey, Earl Ray
AU - Maetzler, Walter
AU - Espay, Alberto J.
AU - Martinez-Martin, Pablo
AU - Stebbins, Glenn T.
AU - Sánchez-Ferro, Álvaro
N1 - Funding Information: MHGM is employee of the Autonomous University of Madrid and HM‐Puerta del Sur University Hospital. RLMF is an employee CHDI Management, Inc. EC has served on the advisory board for Abbvie and Allergan. TAM has served on the advisory board for AbbVie; has received honoraria from International Parkinson and Movement Disorders Society, University of Ottawa, AbbVie, and Ipsen; has received grant support from University of Ottawa Medical Associates, Parkinson Canada, Parkinson Research Consortium, LesLois Foundation, PSI Foundation, University of Ottawa Brain and Mind Institute, and Michael J Fox Foundation; and has been employed by University of Ottawa Medical Associates. AHT has received honoraria from Novartis and grant support from the Toray Science Foundation. LMC receives research support from the Michael J. Fox Foundation (MJFF), receives research support for a clinical trial sponsored by Biogen, and receives royalties from Wolters Kluwel (for book authorship). KD reports employment with Lille University Medical Center. CJFA is an employee of Mitsubishi Tanabe Pharma America, In. BB currently serves as Associate Editor for the ', has received honoraria from serving on the scientific advisory board for Zambon, AbbVie, UCB, and Kyowa Kirin, has received fees for speaking at conferences from AbbVie, Zambon, and Bial and has received research support from the Netherlands Organization for Scientific Research, the Michael J. Fox Foundation, UCB, AbbVie, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson's Foundation, Verily Life Sciences, the Topsector Life Sciences and Health, and the Parkinson Vereniging. FBH has financial interest in ADPM, a company with commercial interests in technology for movement disorders. This conflict has been reviewed and managed by OHSU. She has received grant support from NIH, DoD, Phillips, Adamas, and Medtronic. She serves as consultant for Biogen, Neuropore, Takeda, and Sanofi. AM received support from the NIH (KL2 Career Development Award). He has received grant support from Lundbeck, Abbvie, and Abbott. He has received speaker honoraria from CSL Behring, Cynapsus Therapeutics, Theravance Biopharma, Medtronic, and Abbvie. RR is founding director and owner of the George Huntington Institute, a private research institute focused on clinical and preclinical research in Huntington's disease, and QuantiMedis, a clinical research organization providing Q‐Motor (quantitative motor) services in clinical trials and research. He provided consulting services, advisory board functions, clinical trial services, quantitative motor analyses, and/or lectures for Teva, Pfizer, uniQure, Ipsen, Vaccinex, WAVE, Novartis, Raptor, Omeros, Siena Biotech, Neurosearch Inc., Lundbeck, Medivation, Wyeth, ISIS Pharma, Link Medicine, Prana Biotechnology, MEDA Pharma, Temmler Pharma, Desitin, AOP Orphan, and the Cure Huntington's Disease Initiative Foundation. SSP reports funding from NSW Health and employment by the University of Sydney. ERD has received honoraria for speaking at American Academy of Neurology courses, American Neurological Association, and University of Michigan; received compensation for consulting services from 23andMe, Abbott, AbbVie, American Well, Biogen, Clintrex, DeciBio, Denali Therapeutics, GlaxoSmithKline, Grand Rounds, Karger, Lundbeck, MC10, MedAvante, Medical‐legal services, Mednick Associates, National Institute of Neurological Disorders and Stroke, Olson Research Group, Optio, Prilenia, Putnam Associates, Roche, Sanofi, Shire, Sunovion Pharma, Teva, UCB, and Voyager Therapeutics; research support from AbbVie, Acadia Pharmaceuticals, AMC Health, Biosensics, Burroughs Wellcome Fund, Davis Phinney Foundation, Duke University, Food and Drug Administration, GlaxoSmithKline, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health/National Institute of Neurological Disorders and Stroke, National Science Foundation, Nuredis Pharmaceuticals, Patient‐Centered Outcomes Research Institute, Pfizer, Prana Biotechnology, Raptor Pharmaceuticals, Roche, Safra Foundation, Teva Pharmaceuticals, University of California Irvine; editorial services for Karger Publications; and ownership interests with Blackfynn (data integration company) and Grand Rounds (second opinion service). WM receives or received funding from the European Union (PI of KEEP CONTROL, Co‐PI of IDEA‐FAST), the German Federal Ministry of Education of Research, Michael J. Fox Foundation, Robert Bosch Foundation, Neuroalliance, Sivantos, Lundbeck and Janssen. He received speaker honoraria from Abbvie, Bayer, GlaxoSmithKline, Licher MT, Rölke Pharma, Takeda and UCB, was invited to Advisory Boards of Abbvie, Biogen, Lundbeck and Market Access & Pricing Strategy GmbH, and is an advisory board member of the Critical Path for ' Consortium. He serves as the co‐chair of the MDS Technology Task Force. AJE has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Neuroderm, Neurocrine, Amneal, Adamas, Acadia, Acorda, InTrance, Sunovion, Lundbeck, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Acadia, and Sunovion. PMM reports funding from UCB for the validation study of the Scale for Evaluation of Neuropsychiatric Disorders in Parkinson's Disease (SEND‐PD) and from the International Parkinson and Movement Disorder Society for the Pilot Study of the MDS‐Non‐Motor Symptoms Scale. GTS reports funding from the International Parkinson and Movement Disorder Society for examination of missing values and differential item function analyses of the MDS‐UPDRS. ASF has received funding from the Joint Program for Neurodegenerative Diseases and Carlos III Institute (Grant number AC18/00042) has also received speaker and travel honoraria from Teva, Zambon, Abbvie, and Novartis Pharmaceutical. He owns common stock in Leuko Labs, Inc a company with commercial interests in a Medical Device developed for neutropenia detection. He is also an inventor of a Method and Apparatus for Motor Function characterization (US 2020/0060622 Al) that has been licensed to an independent commercial entity (nQ‐Medical) by the Massachusetts of Technology. Financial disclosures for previous 12 months: Journal of Parkinson s Disease Parkinson s
PY - 2021/2
Y1 - 2021/2
KW - clinical scales
KW - data collection
KW - electronic health records
KW - medical information exchange
UR - http://www.scopus.com/inward/record.url?scp=85098193327&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098193327&partnerID=8YFLogxK
U2 - 10.1002/mdc3.13135
DO - 10.1002/mdc3.13135
M3 - Article
AN - SCOPUS:85098193327
SN - 2330-1619
VL - 8
SP - 208
EP - 214
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
IS - 2
ER -